{"id":"W4321487567","doi":"10.1186/s12885-023-10642-7","title":"INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)","year":2023,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"National Health and Medical Research Council; Bayer HealthCare; Bristol-Myers Squibb","keywords":"Regorafenib; Medicine; Internal medicine; Oncology; Adverse effect; Placebo; Nivolumab; Clinical endpoint; Bevacizumab; Ramucirumab; Progression-free survival; Clinical trial; Cancer; Chemotherapy; Colorectal cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006810676,0.003570241,0.005297421,0.0009153913,0.0006064608,0.002018731,0.001875335,0.003188795,0.01032545],"category_scores_gemma":[0.005817659,0.001282573,0.004737414,0.00105732,0.001897696,0.001669284,0.0009438157,0.003602044,0.001420331],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00148152,"about_ca_system_score_gemma":0.00207649,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00142086,"about_ca_topic_score_gemma":0.003325693,"domain_scores_codex":[0.997025,0.001852413,0.0002445036,0.0004016226,0.0002302948,0.0002461948],"domain_scores_gemma":[0.9971622,0.0007986689,0.0009821036,0.0002776938,0.0002163552,0.0005630052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9851495,0.003685958,0.0002221708,0.001542842,0.001683931,0.00002135918,0.00003570367,0.0002286721,0.001027353,0.0001215911,0.0006571427,0.005623842],"study_design_scores_gemma":[0.9742898,0.02418066,0.0003631593,0.00004757968,0.0004578476,0.000009258077,0.000009742779,0.00008263368,0.00007778974,0.00006981206,0.0004039462,0.000007688072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8504911,0.03262392,0.003827381,0.002519634,0.003513422,0.09088916,0.007368596,0.0006103089,0.008156429],"genre_scores_gemma":[0.8410715,0.01303519,0.008421564,0.00480541,0.002341369,0.1158665,0.005112723,0.0001123084,0.009233364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01032545,"threshold_uncertainty_score":0.03601873,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06799051532900977,"score_gpt":0.4015266076578469,"score_spread":0.3335360923288372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}